Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS

Business Wire January 28, 2020

Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults

Business Wire January 23, 2020

Pfizer's Greenstone and Digital Men's Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate)

Business Wire January 23, 2020

Insilico enters into research collaboration with Pfizer Inc. to explore novel data and artificial intelligence system for potential therapeutic targets

PR Newswire January 14, 2020

Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer's Disease and Parkinson's Disease from Pfizer Inc.

GlobeNewswire January 13, 2020

Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer's Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate

GlobeNewswire January 13, 2020

Markets Shrug Off Cold Jobs Report, Dow Approaches 29K

Livemoney January 10, 2020

eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types

GlobeNewswire January 9, 2020

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire January 7, 2020

BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

PR Newswire January 6, 2020

Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program

PR Newswire December 23, 2019

U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy

Business Wire December 18, 2019

Pfizer and Mylan Announce Two Future Viatris Board Members

Business Wire December 18, 2019

Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts

Business Wire December 17, 2019

XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer

PR Newswire December 16, 2019

XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer

Business Wire December 16, 2019

Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline

Business Wire December 16, 2019

Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease

Business Wire December 13, 2019

FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis

Business Wire December 12, 2019

Pfizer Unveils Positive Results from Asian Subgroup Analysis of ARCHER 1050

PR Newswire November 27, 2019